X
Xiaohong Song
Researcher at Idun Pharmaceuticals
Publications - 23
Citations - 939
Xiaohong Song is an academic researcher from Idun Pharmaceuticals. The author has contributed to research in topics: Cancer & Kinase. The author has an hindex of 8, co-authored 23 publications receiving 902 citations.
Papers
More filters
Journal ArticleDOI
Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.
Cheol-Min Park,Milan Bruncko,Jessica Adickes,Joy Bauch,Hong Ding,Kunzer Aaron R,Kennan C. Marsh,Paul Nimmer,Alexander R. Shoemaker,Xiaohong Song,Stephen K. Tahir,Christin Tse,Wang Xilu,Michael D. Wendt,Xiufen Yang,Haichao Zhang,Stephen W. Fesik,Saul H. Rosenberg,Steven W. Elmore +18 more
TL;DR: Targeted modifications at three key positions of 1 resulted in a 20-fold improvement in the pharmacokinetic/pharmacodynamic relationship (PK/PD) between oral exposure (AUC) and in vitro efficacy in human tumor cell lines (EC 50).
Journal ArticleDOI
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
Milan Bruncko,Thorsten Oost,Barbara A. Belli,Hong Ding,Mary K. Joseph,Kunzer Aaron R,Darlene Martineau,Mcclellan William J,Michael J. Mitten,Shi-Chu Ng ng,Paul Nimmer,Tilman Oltersdorf,Cheol-Min Park,Andrew M. Petros,Alexander R. Shoemaker,Xiaohong Song,Wang Xilu,Wendt Michael D,Haichao Zhang,Stephen W. Fesik,Saul H. Rosenberg,Steven W. Elmore +21 more
TL;DR: Compound 2 demonstrated single agent efficacy against human follicular lymphoma cell lines that overexpress Bcl-2, and efficacy in a murine xenograft model of lymphoma when given both as a single agent and in combination with etoposide.
Patent
N-acylsulfonamide apoptosis promoters
Milan Bruncko,Hong Ding,Steven W. Elmore,Kunzer Aaron R,Christopher L. Lynch,Mcclellan William J,Cheol-Min Park,Andrew M. Petros,Xiaohong Song,Wang Xilu,Noah Tu,Wendt Michael D +11 more
TL;DR: In this paper, Nacylsulfonamide compounds which inhibit the activity of anti-apoptotic protein family members, compositions containing the compounds and uses of the compounds for preparing medicaments for treating diseases were discussed.
Journal ArticleDOI
Syntheses of Potent, Selective, and Orally Bioavailable Indazole-Pyridine Series of Protein Kinase B/Akt Inhibitors with Reduced Hypotension
Gui-Dong Zhu,Viraj B. Gandhi,Jianchun Gong,Sheela A. Thomas,Keith W. Woods,Xiaohong Song,T. Li,R.B. Diebold,Yan Luo,Xuesong Liu,Ran Guan,Klinghofer,Eric F. Johnson,Jennifer J. Bouska,Amanda M. Olson,Kennan C. Marsh,Vincent S. Stoll,Mulugeta Mamo,James S. Polakowski,Thomas J Campbell,Ruth L. Martin,Gary Gintant,Thomas D. Penning,Qun Li,Saul H. Rosenberg,Vincent L. Giranda +25 more
TL;DR: To improve the selectivity of these Akt inhibitors over other protein kinases, a nitrogen atom was incorporated into selected phenyl analogues of 7 at the C-6 position of the methyl indazole scaffold and resulted in the discovery of inhibitor 37c with greater potency, selectivity, and improved cardiovascular safety profile.
Journal ArticleDOI
Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.
Qun Li,Keith W. Woods,Sheela A. Thomas,Gui-Dong Zhu,Garrick Packard,John E. Fisher,Tongmei Li,Jianchun Gong,Jürgen Dinges,Xiaohong Song,Jason N. Abrams,Yan Luo,Eric F. Johnson,Yan Shi,Xuesong Liu,Vered Klinghofer,Ron Des Jong,Tilman Oltersdorf,Vincent S. Stoll,Clarissa G. Jakob,Saul H. Rosenberg,Vincent L. Giranda +21 more
TL;DR: 3,4'-bispyridinylethylene series led to the discovery of 3-isoquinolinylpyridine 13a as a potent PKB/Akt inhibitor with an IC(50) of 1.3nM against Akt1.